Intellectual Property India Publishes Patent Application for 'Mitigation Of Therapeutic Protein Fragmentation During Cell Culture Harvest Processes' Filed by Amgen Inc.

MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202517073056 A) filed by Amgen Inc., Thousand Oaks, U.S.A., on July 31, for 'mitigation of therapeutic protein fragmentation during cell culture harvest processes.'

Inventor(s) include Xiao, Gang; Chung, Hyo Seon; Luo, Quanzhou; Eris, Tamer; Basconi, Joseph Edward; Zhao, Xiaoyang; Bondarenko, Pavel; Petty, Krista Marie; and Kaltenbrunner, Oliver.

The application for the patent was published on Aug. 22, under issue no. 34/2025.

According to the abstract released by the Intellectual Property India: "Disclosed herein are methods for harvesting an antibody as recombinant protein comprising an asparaginyl endopeptidase (AEP, legumain) cleavage site having amino acids NF by keeping pH after fermentation at 4.6 to 5.3 for acidification to precipitate impurities, to prevent autocleavage of proenzyme and thus activation of peptidase at lower pH, as well as methods for inhibiting cleavage of a recombinant protein comprising an AEP cleavage site, during a biomanufacturing process."

The patent application was internationally filed on Feb. 01, 2024, under International application No.PCT/US2024/013950.

Disclaimer: Curated by HT Syndication.